Moderna (MRNA) earnings Q1 2021

Moderna (MRNA) earnings Q1 2021

A nurse attracts a Moderna coronavirus illness (COVID-19) vaccine, at East Valley Neighborhood Well being Heart in La Puente, California, March 5, 2021.

Lucy Nicholson | Reuters

Moderna mentioned its Covid-19 vaccine is 96% efficient in youngsters ages 12 to 17, based on early information launched with the corporate’s first-quarter earnings Thursday.

The younger biotech firm, which turned its first quarterly revenue ever, additionally mentioned it plans to submit information on its vaccine for adults to the FDA for full approval later this month.

Just like adults, the shot in teenagers was additionally usually nicely tolerated with no severe security considerations recognized to this point, the corporate mentioned.

This is how Moderna did in contrast with what Wall Avenue anticipated, based on common estimates compiled by Refinitiv:

  • EPS: $2.84 per share versus $2.39 per share anticipated
  • Income: $1.94 billion versus $2.03 billion anticipated

Moderna’s Covid-19 vaccine generated $1.7 billion in gross sales, based on the earnings report.

The corporate raised its 2021 gross sales forecast for its vaccine to $19.2 billion, up from its earlier forecast of $18.4 billion. Earlier this week, rival Pfizer additionally raised its vaccine sale forecast, predicting full-year gross sales of $26 billion.

“Within the first quarter, the Moderna staff delivered on its provide commitments to many governments and helped shield greater than 100 million folks,” Moderna CEO Stephane Bancel mentioned in a press launch. “This accomplishment translated into our first worthwhile quarter within the firm’s historical past, after 10 years of scientific innovation and several other billion {dollars} invested to make our mRNA platform a actuality.”

Moderna was the second firm to achieve U.S. authorization for its Covid vaccine behind Pfizer.

On Wednesday, the corporate introduced a booster shot of its vaccine generated a promising immune response in opposition to the B.1.351 and P.1 variants first recognized in South Africa and Brazil, respectively.

This can be a growing story. Please examine again for updates.

Total
0
Shares
Leave a Reply

Your email address will not be published. Required fields are marked *

Related Posts